tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
PremiumRatingsCompass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
1M ago
Compass Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Compass Therapeutics Reports Q3 2025 Financial Results
2M ago
Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position
Premium
Ratings
Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position
2M ago
Promising Outlook for Compass Therapeutics: Buy Rating Backed by COMPANION-002 Trial Success and Market Potential
PremiumRatingsPromising Outlook for Compass Therapeutics: Buy Rating Backed by COMPANION-002 Trial Success and Market Potential
2M ago
Buy Rating for Compass Therapeutics Driven by Promising Clinical Trial Data and Strategic Enrollment
Premium
Ratings
Buy Rating for Compass Therapeutics Driven by Promising Clinical Trial Data and Strategic Enrollment
2M ago
Compass Therapeutics initiated with an Outperform at LifeSci Capital
Premium
The Fly
Compass Therapeutics initiated with an Outperform at LifeSci Capital
3M ago
Compass Therapeutics announces common stock offering, no amount given
PremiumThe FlyCompass Therapeutics announces common stock offering, no amount given
4M ago
Compass Therapeutics price target raised to $12 from $10 at Guggenheim
Premium
The Fly
Compass Therapeutics price target raised to $12 from $10 at Guggenheim
4M ago
Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions
Premium
Company Announcements
Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100